デフォルト表紙
市場調査レポート
商品コード
1439636

がん診断 - 世界市場の考察、競合情勢、市場予測(2030年)

Cancer Diagnostic - Market Insights, Competitive Landscape, and Market Forecast - 2030

出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 150 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.89円
がん診断 - 世界市場の考察、競合情勢、市場予測(2030年)
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2~10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のがん診断の市場規模は、2023年に1,251億3,000万米ドル、2030年までに2,148億8,000万米ドルに達し、2024年~2030年の予測期間にCAGRで9.43%の成長が見込まれます。がん診断の製品とサービスに対する需要の増加は、世界中で報告されているがん患者の急増が主な原因です。加えて、先進のがん診断製品の開発に注力するメーカーの増加、さまざまながん診断ラボの設立、患者のがんの早期発見と管理に関する認識を高める政府の取り組みの高まりなどが、今後数年間、世界のがん診断市場を牽引すると予測されます。

がん診断の市場力学

がん診断市場は、世界のがん患者の急増により、現在勢いを増しています。GLOBOCANが2020年に発表したデータによると、世界中で約1,929万2,789件の新規がん症例が報告されています。さらに、世界保健機関(WHO)の2022年のデータによると、2020年に世界中で推定1,000万人ががんで死亡しています。したがって、適切ながん管理にはがんの早期発見が必要であり、これががん診断の需要の増加につながり、市場を牽引しています。

さらに、上記のデータによると、タバコの使用、アルコールの使用、不健康な食事、運動不足、発がん性感染症、大気汚染はがんの危険因子です。例えば、2018年に診断されたがんの約13%は、WHO(2022)によると、ヘリコバクターピロリ、ヒトパピローマウイルス(HPV)、B型肝炎ウイルス、C型肝炎ウイルス、エプスタインバーウイルスなどの発がん性の感染症に起因しています。

さらに、さまざまながん診断製品の開発における技術革新も、今後数年間の市場に寄与する可能性があります。がん検出の精度、スピード、効率を向上させるAI技術のがん医療への統合も、がん診断市場を押し上げる見込みです。例えば、2022年11月、FDAは乳がんを検出するLunit AIソリューションに510(k)認可を与えました。

したがって、前述のすべての要因が予測期間にがん診断市場を強化すると見込まれます。

しかし、がん画像診断機器に伴う副作用やがん診断製品の高いコストが、世界のがん診断市場を阻害する可能性が高いです。

さらに、前例のないCOVID-19パンデミックは、がん診断市場にマイナスの影響を与えました。これは、感染伝播を抑制するために世界のほとんどの国が厳しい規制を実施したためです。さらに、医療システムの能力を維持し、高リスクの患者をウイルスへの暴露から守ることに重点が移ったため、がん患者は治療へのアクセスにおいて課題が増加しました。例えば、National Cancer Institute(2022)が提供したデータによると、COVID-19パンデミックによるロックダウン制限に関連する課題のほか、2020年3月だけでも、COVID-19によって肺がん検診の予約が800件以上延期されたことが確認されています。

がん診断市場のセグメント分析

がん診断製品タイプ製品タイプセグメントでは、試薬・キットタイプが66%と大きな市場シェアを占めており、予測期間にもこの動向は続く見込みです。これは、がん細胞における細胞シグナル伝達、細胞増殖と生存率、がん抑制遺伝子、生理活性タンパク質などを検出するのに用いる試薬・キットが広く利用可能であるためです。

さらに、さまざまな種類のがんの早期発見や適切な管理に役立つ新しい試薬やキットが規制当局によって承認されたことも、このセグメントの市場成長を押し上げると予測されます。

例えば、革新的な次世代シーケンシング(NGS)ソリューションの体外診断(IVD)企業であるPillar Biosciencesは、2022年08月05日、非小細胞肺がん(NSCLC)と大腸がん(CRC)腫瘍由来のDNAにおける体細胞変異を定性的に検出するNGS組織ベースのコンパニオン診断検査であるoncoReveal(TM)Dx Lung and Colon Cancer Assayの市販前承認(PMA)を取得しました。

当レポートでは、世界のがん診断市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 がん診断市場レポートのイントロダクション

第2章 がん診断市場のエグゼクティブサマリー

  • 調査範囲
  • 市場の概要
  • 競合の評価
  • 財務ベンチマーク

第3章 規制分析

  • 米国
  • 欧州
  • 日本
  • 中国

第4章 がん診断市場の主な要因の分析

  • がん診断市場の促進要因
    • 世界中でのガンの罹患率の増加
    • 製品開発における技術革新
    • がん診断メーカーの戦略的事業活動の拡大
    • がん診断製品の発売の増加
  • がん診断市場の抑制要因と課題
    • がん画像診断装置に伴う副作用
    • がん診断製品の高いコスト、一部の製品限られた効能
  • がん診断市場の機会
    • がん診断に対する意識の向上
    • 発展途上国における医療支出の増加

第5章 がん診断のポーターのファイブフォース分析

第6章 がん診断市場に対するCOVID-19の影響分析

第7章 がん診断市場のレイアウト

  • タイプ別
    • 製品タイプ
    • サービス
  • 手法別
    • 分子診断
    • 画像診断
    • 内視鏡検査
    • 生検
  • がんタイプ別
    • 乳がん
    • 大腸がん
    • 肺がん
    • 前立腺がん
    • その他
  • エンドユーザー別
    • 病院
    • 診断研究所
    • 画像診断センター
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第8章 がん診断:世界の企業シェア分析 - 主要3~5社

第9章 がん診断の企業と製品のプロファイル

  • Pillar Biosciences, Inc.
  • Hologic Inc.
  • CD Genomics
  • Natera, Inc.
  • Agendia Inc.
  • Biodesix Inc.
  • INOVIQ Ltd.
  • HTG Molecular Diagnostics Inc.
  • Bio-Rad Laboratories, Inc.
  • Koninklijke Philips N.V.
  • FUJIFILM Holdings Corporation
  • Abbott
  • General Electric Company
  • Thermo Fisher Scientific Inc.
  • NeoGenomics Laboratories
  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies Inc
  • Guardant Health
  • Illumina, Inc.
  • QIAGEN

第10章 KOLの見解

第11章 プロジェクトのアプローチ

第12章 DelveInsightについて

第13章 免責事項とお問い合わせ

図表

List of Tables

  • Table 1 Competitive Analysis
  • Table 2 COVID-19 Impact Analysis on Cancer Diagnostic Market
  • Table 3 Cancer Diagnostic Market Analysis in Global (2021-2030)
  • Table 4 Cancer Diagnostic Market Analysis in Global by Type (2021-2030)
  • Table 5 Cancer Diagnostic Market Analysis in Global by Technique (2021-2030)
  • Table 6 Cancer Diagnostic Market Analysis in Global by Cancer Type (2021-2030)
  • Table 7 Cancer Diagnostic Market Analysis in Global by End User (2021-2030)
  • Table 8 Cancer Diagnostic Market Analysis in Global by Geography (2021-2030)
  • Table 9 Cancer Diagnostic Market Analysis in North America (2021-2030)
  • Table 15 Cancer Diagnostic Market Analysis in the US (2021-2030)
  • Table 16 Cancer Diagnostic Market Analysis in Canada (2021-2030)
  • Table 17 Cancer Diagnostic Market Analysis in Mexico (2021-2030)
  • Table 18 Cancer Diagnostic Market Analysis in Europe (2021-2030)
  • Table 24 Cancer Diagnostic Market Analysis in France (2021-2030)
  • Table 25 Cancer Diagnostic Market Analysis in Germany (2021-2030)
  • Table 26 Cancer Diagnostic Market Analysis in the UK (2021-2030)
  • Table 27 Cancer Diagnostic Market Analysis in Italy (2021-2030)
  • Table 28 Cancer Diagnostic Market Analysis in Spain (2021-2030)
  • Table 29 Cancer Diagnostic Market Analysis in Russia (2021-2030)
  • Table 30 Cancer Diagnostic Market Analysis in Rest of Europe (2021-2030)
  • Table 31 Cancer Diagnostic Market Analysis in Asia-Pacific (2021-2030)
  • Table 37 Cancer Diagnostic Market Analysis in China (2021-2030)
  • Table 38 Cancer Diagnostic Market Analysis in Japan (2021-2030)
  • Table 39 Cancer Diagnostic Market Analysis in India (2021-2030)
  • Table 40 Cancer Diagnostic Market Analysis in Australia (2021-2030)
  • Table 41 Cancer Diagnostic Market Analysis in South Korea (2021-2030)
  • Table 42 Cancer Diagnostic Market Analysis in Rest of Asia-Pacific (2021-2030)
  • Table 43 Cancer Diagnostic Market Analysis in Rest of World (2021-2030)
  • Table 49 Cancer Diagnostic Market Analysis in the Middle East (2021-2030)
  • Table 50 Cancer Diagnostic Market Analysis in Africa (2021-2030)
  • Table 51 Cancer Diagnostic Market Analysis in South America (2021-2030)

List of Figures

  • Figure 1 Competitive Analysis
  • Figure 2 COVID-19 Impact Analysis on Cancer Diagnostic Market
  • Figure 3 Cancer Diagnostic Market Analysis in Global (2021-2030)
  • Figure 4 Cancer Diagnostic Market Analysis in Global by Type (2021-2030)
  • Figure 5 Cancer Diagnostic Market Analysis in Global by Technique (2021-2030)
  • Figure 6 Cancer Diagnostic Market Analysis in Global by Cancer Type (2021-2030)
  • Figure 7 Cancer Diagnostic Market Analysis in Global by End User (2021-2030)
  • Figure 8 Cancer Diagnostic Market Analysis in Global by Geography (2021-2030)
  • Figure 9 Cancer Diagnostic Market Analysis in North America (2021-2030)
  • Figure 15 Cancer Diagnostic Market Analysis in the US (2021-2030)
  • Figure 16 Cancer Diagnostic Market Analysis in Canada (2021-2030)
  • Figure 17 Cancer Diagnostic Market Analysis in Mexico (2021-2030)
  • Figure 18 Cancer Diagnostic Market Analysis in Europe (2021-2030)
  • Figure 24 Cancer Diagnostic Market Analysis in France (2021-2030)
  • Figure 25 Cancer Diagnostic Market Analysis in Germany (2021-2030)
  • Figure 26 Cancer Diagnostic Market Analysis in the UK (2021-2030)
  • Figure 27 Cancer Diagnostic Market Analysis in Italy (2021-2030)
  • Figure 28 Cancer Diagnostic Market Analysis in Spain (2021-2030)
  • Figure 29 Cancer Diagnostic Market Analysis in Russia (2021-2030)
  • Figure 30 Cancer Diagnostic Market Analysis in Rest of Europe (2021-2030)
  • Figure 31 Cancer Diagnostic Market Analysis in Asia-Pacific (2021-2030)
  • Figure 37 Cancer Diagnostic Market Analysis in China (2021-2030)
  • Figure 38 Cancer Diagnostic Market Analysis in Japan (2021-2030)
  • Figure 39 Cancer Diagnostic Market Analysis in India (2021-2030)
  • Figure 40 Cancer Diagnostic Market Analysis in Australia (2021-2030)
  • Figure 41 Cancer Diagnostic Market Analysis in South Korea (2021-2030)
  • Figure 42 Cancer Diagnostic Market Analysis in Rest of Asia-Pacific (2021-2030)
  • Figure 43 Cancer Diagnostic Market Analysis in Rest of World (2021-2030)
  • Figure 49 Cancer Diagnostic Market Analysis in the Middle East (2021-2030)
  • Figure 50 Cancer Diagnostic Market Analysis in Africa (2021-2030)
  • Figure 51 Cancer Diagnostic Market Analysis in South America (2021-2030)
  • Figure 52 Market Drivers
  • Figure 53 Market Barriers
  • Figure 54 Market Opportunities
  • Figure 55 PORTER's Five Force Analysis
目次
Product Code: DIMDCL0473

Cancer Diagnostic Market By Type (Product Type [Reagent & Kits And Instruments], And Services), By Technique (Molecular Diagnostic [Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Fluorescent In-Situ Hybridization (FISH), Microarray, Immunohistochemistry], Diagnostic Imaging [Ultrasound & Radiology, Mammography, MRI Scan, CT Scan, Nuclear Medicine Scans], Endoscopy, Biopsy [Standard Biopsy And Liquid Biopsy]), By Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Others), By End-User (Hospitals, Diagnostic Laboratories, Diagnostic Imaging Centers, Others), by geography, is expected to grow at a significant CAGR forecast till 2030 owing to the growing burden cancer across the globe and rise in various product launches for efficient detection of cancer

The global cancer diagnostic market was valued at USD 125.13 billion in 2023, growing at a CAGR of 9.43% during the forecast period from 2024 to 2030, to reach USD 214.88 billion by 2030. The increase in demand for cancer diagnostic products and services is predominantly attributed to the spike in the cancer cases reported worldwide. In addition, growing manufacturers focus to develop advanced cancer diagnostic products, the establishment of various cancer diagnostic labs, and rising government initiatives to raise awareness regarding early detection and management of cancer among the patients, and others are anticipated to drive the global cancer diagnostic market during the forthcoming years.

Cancer Diagnostic Market Dynamics:

The market for cancer diagnostics is gaining momentum at present due to the surge in cancer cases across the globe. According to the data published by the GLOBOCAN in the year 2020, approximately 19,292,789 new cases of cancer were reported worldwide. Furthermore, as per the World Health Organization (WHO) 2022 data, cancer accounted for an estimated 10 million deaths across the globe in the year 2020. Thus, for proper cancer management, early detection of cancer is necessary which would lead to an increased demand for cancer diagnosis thereby propelling the market.

Additionally, as per the above-mentioned data, tobacco use, alcohol use, unhealthy diet, physical inactivity, carcinogenic infections, and air pollution are some of the risk factors for cancer. For instance, in the year 2018, about 13% of cancer diagnosed were attributed to carcinogenic infections such as Helicobacter pylori, human papillomavirus (HPV), hepatitis B virus, hepatitis C virus, and Epstein-Barr virus, as per the WHO, 2022.

Furthermore, technical innovation in the development of a variety of cancer diagnostic products would also contribute to the market in the forthcoming years. Integration of Artificial Intelligence (AI) technology in cancer care to improve the accuracy, speed and efficiency of cancer detection will also boost the cancer diagnostic market. For instance, in November 2022, FDA granted 510(k) clearance for Lunit AI solution to detect breast cancer.

Hence, all the aforementioned factors are projected to bolster the cancer diagnostic market during the forecasted period.

However, side effects associated with cancer imaging devices and the high cost of cancer diagnostic products are likely to impede the global cancer diagnostic market.

Additionally, the unprecedented COVID-19 pandemic had a negative impact on the cancer diagnostic market. This is due to the implementation of stringent regulations by most nations worldwide to curb infection transfer. Moreover, owing to the shift in focus on preserving health system capacity and also protecting high-risk patients from exposure to the virus, cancer patients have faced increased challenges in accessing care. For instance, as per the data provided by the National Cancer Institute 2022, besides the challenges associated with the lockdown restrictions due to the COVID-19 pandemic, it was observed that in March 2020 alone, COVID-19 forced the postponement of more than 800 appointments for lung cancer screening.

Cancer Diagnostic Market Segment Analysis:

Cancer Diagnostic Market By Type (Product Type [Reagent & Kits And Instruments], And Services), By Technique (Molecular Diagnostic [Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Fluorescent In-Situ Hybridization (FISH), Microarray, Immunohistochemistry], Diagnostic Imaging [Ultrasound & Radiology, Mammography, MRI Scan, CT Scan, Nuclear Medicine Scans], Endoscopy, Biopsy [Standard Biopsy and Liquid Biopsy]), By Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Others), By End-User (Hospitals, Diagnostic Laboratories, Diagnostic Imaging Centers, Others), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the Cancer Diagnostic product type segment, the reagents & kits type held a significant market share of 66% which is expected to continue during the forecasted period. This is owing to the wide availability of reagents & kits for detecting cell signalling, cell proliferation and viability, tumor suppressor gene, bioactive proteins, and others in cancer cells.

Furthermore, approval of novel reagents and kits, which aid in early detection and proper management of various cancer types, by the regulatory bodies is also expected to boost the market growth for this segment.

For instance, on August 05, 2022, Pillar Biosciences, an innovative next-generation sequencing (NGS) solutions in-vitro diagnostics (IVD) company, received the Premarket Approval (PMA) for its oncoReveal(TM) Dx Lung and Colon Cancer Assay, an NGS tissue-based companion diagnostic test for the qualitative detection of somatic mutations in DNA derived from non-small cell lung cancer (NSCLC) and colorectal (CRC) cancer tumors.

Also, rising research and development activities by the key manufacturers are another factor projected to contribute to the segmental growth of the cancer diagnostic market. For instance, in the year 2020, BD started a clinical trial to verify the clinical effectiveness of the HPV Nucleic Acid Genotyping Assay Kit for cervical cancer.

Thus, all the above-mentioned factors are expected to propel the cancer diagnostic market in the upcoming years.

North America is expected to dominate the overall Cancer Diagnostic Market:

Among all the regions, North America has occupied a major share of 42% in the overall Cancer Diagnostic market in 2020 and will continue to dominate during the forecasted period. This domination is due to significant factors such as the rise in cancer cases, the presence of key manufacturers, well-established healthcare infrastructure, and rising awareness regarding cancer and its proper management, among others.

For instance, as per the GLOBOCAN 2020 data, approximately, 2,281,658 people were diagnosed with cancer in the US in 2020.

Furthermore, the rise in smoking among adults in the country could be a potential factor for lung cancer development which would, in turn, increase the cancer diagnostic market.

For instance, as per the CDC 2020 data, an estimated 34.1 million adults in the United States smoked cigarettes in 2019.

Moreover, approval of products to enhance the imaging technology for various cancer detection would also contribute to the market. Recently, on November 29, 2022, FDA approved Cytalux (pafolacianine), a targeted fluorescent imaging agent intended to assist surgeons in identifying ovarian cancer lesions.

Hence, the interplay of all the above-mentioned factors will augment the cancer diagnostic market in the country during the forecasted period.

Further, the Asia Pacific region has the future potential for the Cancer Diagnostic market. This is predominantly due to the burgeoning cases of cancer, rising risk factors among the population that potentially lead to the development of cancer, growing government initiatives regarding cancer care and its detection, among others. For instance, New Zealand launched Cancer Action Plan 2019-2029, the plans enable the Cancer Control Agency, the Ministry of Health, the sector, and all those affected by cancer to work collaboratively to prevent cancer and improve detection, diagnosis, treatment, and care after treatment. Thus, all the factors stated above will make APAC the fastest growing cancer diagnostic market in the forthcoming years.

Cancer Diagnostic Market Key Players:

Some of the key market players operating in the Cancer Diagnostic market include Pillar Biosciences, Inc., Hologic Inc., CD Genomics, Natera, Inc., Agendia Inc., Biodesix Inc., INOVIQ Ltd., HTG Molecular Diagnostics Inc., Bio-Rad Laboratories, Inc., Koninklijke Philips N.V., FUJIFILM Holdings Corporation, Abbott, General Electric Company, Thermo Fisher Scientific Inc., NeoGenomics Laboratories, F. Hoffmann-La Roche Ltd, Agilent Technologies Inc, Guardant Health, Illumina, Inc., QIAGEN, and others.

Recent Developmental Activities in the Cancer Diagnostic Market:

In November 2022, Hologic, Inc. commercially launched its new Genius(TM) Digital Diagnostics System in Europe. The Genius Digital Diagnostics System is the next generation of cervical cancer screening that combines deep learning-based artificial intelligence (AI) with advanced volumetric imaging technology to help identify pre-cancerous lesions and cervical cancer cells in women.

In June 2022, NeoGenomics completed its acquisition for Inivata Ltd, a global, commercial-stage liquid biopsy platform company headquartered in Cambridge, England.

In August 2020, HTG Molecular Diagnostics, Inc. signed a commercialization and distribution agreement (Master Agreement) with QIAGEN Manchester Limited, a wholly-owned subsidiary of QIAGEN N.V. for companion diagnostic (CDx) assays based on HTG EdgeSeq, HTG's novel RNA platform.

Key Takeaways from the Cancer Diagnostic Market Report Study

Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)

The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Cancer Diagnostic market.

Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years

Key companies dominating the Global Cancer Diagnostic Market.

Various opportunities available for the other competitor in the Cancer Diagnostic Market space.

What are the top-performing segments in 2023? How these segments will perform in 2030.

Which are the top-performing regions and countries in the current market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for Cancer Diagnostic market growth in the coming future?

Target Audience who can be benefited from the Cancer Diagnostic Market Report Study

Cancer Diagnostic providers

Research organizations and consulting companies

Cancer Diagnostic-related organization, association, forum, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders in Cancer Diagnostic

Various End-users who want to know more about the Cancer Diagnostic Market and the latest technological developments in the Cancer Diagnostic market.

Frequently Asked Questions for the Cancer Diagnostic Market:

1. What is Cancer Diagnostic?

Cancer Diagnostic is a necessary step towards the proper management of cancer and its progression. There is no single test that can accurately diagnose cancer; the complete evaluation usually requires a thorough history and physical examination along with diagnostics testing. Effective diagnostic testing is used to confirm or eliminate the presence of disease, monitor the disease process, and plan for and evaluate the effectiveness of treatment. Diagnostic procedures for cancer may include lab tests, tumor biopsy, endoscopic examination, and imaging.

2. What is the market for Global Cancer Diagnostic?

The global cancer diagnostic market was valued at USD 125.13 billion in 2023, growing at a CAGR of 9.43% during the forecast period from 2024 to 2030, to reach USD 214.88 billion by 2030.

3. What are the drivers for the Global Cancer Diagnostic?

The major factors driving the demand for Cancer Diagnostic are the rising cases of cancer across the globe. Moreover, technological innovation in cancer diagnostic products, increase in product launches, and rise in business expansion activities among key players, and others are expected to propel the cancer diagnostic market.

4. What are the key players operating in Global Cancer Diagnostic?

Some of the key market players operating in the Cancer Diagnostic market include Pillar Biosciences, Inc., Hologic Inc., CD Genomics, Natera, Inc., Agendia Inc., Biodesix Inc., INOVIQ Ltd., HTG Molecular Diagnostics Inc., Bio-Rad Laboratories, Inc., Koninklijke Philips N.V., FUJIFILM Holdings Corporation, Abbott, General Electric Company, Thermo Fisher Scientific Inc., NeoGenomics Laboratories, F. Hoffmann-La Roche Ltd, Agilent Technologies Inc, Guardant Health, Illumina, Inc., QIAGEN, and others.

5. Which region has the highest share in the Cancer Diagnostic market?

Among all the regions, North America has occupied a major share of 42% in the overall Cancer Diagnostic market in 2020 and will continue to dominate during the forecasted period. This domination is due to significant factors such as the rise in cancer cases, the presence of key manufacturers, well-established healthcare infrastructure, and rising awareness regarding cancer and its proper management, among others.

Table of Contents

1.Cancer Diagnostic Market Report Introduction

2. Cancer Diagnostic Market Executive summary

  • 2.1 Scope of the Study
  • 2.2 Market at Glance
  • 2.3 Competitive Assessment
  • 2.4 Financial Benchmarking

3. Regulatory Analysis

  • 3.1 The United States
  • 3.2 Europe
  • 3.3 Japan
  • 3.4 China

4. Cancer Diagnostic Market Key factors analysis

  • 4.1 Cancer Diagnostic Market Drivers
    • 4.1.1 Growing Incidence of Cancer across the Globe
    • 4.1.2 Technical Innovation in Product Development
    • 4.1.3 Growing Strategic Business Activities among Cancer Diagnostic Product Manufacturers
    • 4.1.4 Rising Launch of Cancer Diagnostic Products
  • 4.2 Cancer Diagnostic Market Restraints and Challenges
    • 4.2.1 Side Effects Associated with the Cancer Imaging Devices
    • 4.2.2 High Cost of Cancer Diagnostic Product and Limited Efficiency of Some Products
  • 4.3 Cancer Diagnostic Market Opportunities
    • 4.3.1 Increasing Awareness about Cancer Diagnostic
    • 4.3.2 Increasing Healthcare Expenditure in Developing Countries

5. Cancer Diagnostic Porter's Five Forces Analysis

  • 5.1 Bargaining Power of Suppliers
  • 5.2 Bargaining Power of Consumers
  • 5.3 Threat of New Entrants
  • 5.4 Threat of Substitutes
  • 5.5 Competitive Rivalry

6. COVID-19 Impact Analysis on Cancer Diagnostic Market

7. Cancer Diagnostic Market layout

  • 7.1 By Type
    • 7.1.1 Product Type
      • 7.1.1.1 Reagents & Kits
      • 7.1.1.2 Instruments
    • 7.1.2 Services
  • 7.2 By Technique
    • 7.2.1 Molecular Diagnostic
      • 7.2.1.1 Polymerase Chain Reaction
      • 7.2.1.2 Next Generation Sequencing
      • 7.2.1.3 Fluorescent In-Situ Hybridization
      • 7.2.1.4 Microarray
      • 7.2.1.5 Immunohistochemistry
    • 7.2.2 Diagnostic Imaging
      • 7.2.2.1 Ultrasound & Radiology
      • 7.2.2.2 Mammography
      • 7.2.2.3 MRI Scan
      • 7.2.2.4 CT Scan
      • 7.2.2.5 Nuclear Medicine Scans
    • 7.2.3 Endoscopy
    • 7.2.4 Biopsy
      • 7.2.4.1 Standard Biopsy
      • 7.2.4.2 Liquid Biopsy
  • 7.3 By Cancer Type
    • 7.3.1 Breast Cancer
    • 7.3.2 Colorectal Cancer
    • 7.3.3 Lung Cancer
    • 7.3.4 Prostate Cancer
    • 7.3.5 Others
  • 7.4 By End-user
    • 7.4.1 Hospitals
    • 7.4.2 Diagnostic Laboratories
    • 7.4.3 Diagnostic Imaging Centers
    • 7.4.4 Others
  • 7.5 By Geography
    • 7.5.1 North America
      • 7.5.1.1 United States
      • 7.5.1.2 Canada
      • 7.5.1.3 Mexico
    • 7.5.2 Europe
      • 7.5.2.1 France
      • 7.5.2.2 Germany
      • 7.5.2.3 United Kingdom
      • 7.5.2.4 Italy
      • 7.5.2.5 Spain
      • 7.5.2.6 Russia
      • 7.5.2.7 Rest of Europe
    • 7.5.3 Asia-Pacific
      • 7.5.3.1 China
      • 7.5.3.2 Japan
      • 7.5.3.3 India
      • 7.5.3.4 Australia
      • 7.5.3.5 South Korea
      • 7.5.3.6 Rest of Asia Pacific
    • 7.5.4 Rest of the World (RoW)
      • 7.5.4.1 Middle East
      • 7.5.4.2 Africa
      • 7.5.4.3 South America

8. Cancer Diagnostic Global Company Share Analysis - Key 3-5 Companies

9. Cancer Diagnostic Company and Product Profiles

  • 9.1 Pillar Biosciences, Inc.
    • 9.1.1. Company Overview
    • 9.1.2. Company Snapshot
    • 9.1.3. Financial Overview
    • 9.1.4 Product Listing
    • 9.1.5. Entropy
  • 9.2 Hologic Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Company Snapshot
    • 9.2.3. Financial Overview
    • 9.2.4 Product Listing
    • 9.2.5. Entropy
  • 9.3 CD Genomics
    • 9.3.1. Company Overview
    • 9.3.2. Company Snapshot
    • 9.3.3. Financial Overview
    • 9.3.4 Product Listing
    • 9.3.5. Entropy
  • 9.4 Natera, Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Company Snapshot
    • 9.4.3. Financial Overview
    • 9.4.4 Product Listing
    • 9.4.5. Entropy
  • 9.5 Agendia Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Company Snapshot
    • 9.5.3. Financial Overview
    • 9.5.4 Product Listing
    • 9.5.5. Entropy
  • 9.6 Biodesix Inc.
    • 9.6.1. Company Overview
    • 9.6.2. Company Snapshot
    • 9.6.3. Financial Overview
    • 9.6.4 Product Listing
    • 9.6.5. Entropy
  • 9.7 INOVIQ Ltd.
    • 9.7.1. Company Overview
    • 9.7.2. Company Snapshot
    • 9.7.3. Financial Overview
    • 9.7.4 Product Listing
    • 9.7.5. Entropy
  • 9.8 HTG Molecular Diagnostics Inc.
    • 9.8.1. Company Overview
    • 9.8.2. Company Snapshot
    • 9.8.3. Financial Overview
    • 9.8.4 Product Listing
    • 9.8.5. Entropy
  • 9.9 Bio-Rad Laboratories, Inc.
    • 9.9.1. Company Overview
    • 9.9.2. Company Snapshot
    • 9.9.3. Financial Overview
    • 9.9.4 Product Listing
    • 9.9.5. Entropy
  • 9.10 Koninklijke Philips N.V.
    • 9.10.1. Company Overview
    • 9.10.2. Company Snapshot
    • 9.10.3. Financial Overview
    • 9.10.4 Product Listing
    • 9.10.5. Entropy
  • 9.11 FUJIFILM Holdings Corporation
    • 9.11.1. Company Overview
    • 9.11.2. Company Snapshot
    • 9.11.3. Financial Overview
    • 9.11.4 Product Listing
    • 9.11.5. Entropy
  • 9.12 Abbott
    • 9.12.1. Company Overview
    • 9.12.2. Company Snapshot
    • 9.12.3. Financial Overview
    • 9.12.4 Product Listing
    • 9.12.5. Entropy
  • 9.13 General Electric Company
    • 9.13.1. Company Overview
    • 9.13.2. Company Snapshot
    • 9.13.3. Financial Overview
    • 9.13.4 Product Listing
    • 9.13.5. Entropy
  • 9.14 Thermo Fisher Scientific Inc.
    • 9.14.1. Company Overview
    • 9.14.2. Company Snapshot
    • 9.14.3. Financial Overview
    • 9.14.4 Product Listing
    • 9.14.5. Entropy
  • 9.15 NeoGenomics Laboratories
    • 9.15.1. Company Overview
    • 9.15.2. Company Snapshot
    • 9.15.3. Financial Overview
    • 9.15.4 Product Listing
    • 9.15.5. Entropy
  • 9.16 F. Hoffmann-La Roche Ltd
    • 9.16.1. Company Overview
    • 9.16.2. Company Snapshot
    • 9.16.3. Financial Overview
    • 9.16.4 Product Listing
    • 9.16.5. Entropy
  • 9.17 Agilent Technologies Inc
    • 9.17.1. Company Overview
    • 9.17.2. Company Snapshot
    • 9.17.3. Financial Overview
    • 9.17.4 Product Listing
    • 9.17.5. Entropy
  • 9.18 Guardant Health
    • 9.18.1. Company Overview
    • 9.18.2. Company Snapshot
    • 9.18.3. Financial Overview
    • 9.18.4 Product Listing
    • 9.18.5. Entropy
  • 9.19 Illumina, Inc.
    • 9.19.1. Company Overview
    • 9.19.2. Company Snapshot
    • 9.19.3. Financial Overview
    • 9.19.4 Product Listing
    • 9.19.5. Entropy
  • 9.20 QIAGEN
    • 9.20.1. Company Overview
    • 9.20.2. Company Snapshot
    • 9.20.3. Financial Overview
    • 9.20.4 Product Listing
    • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us